期刊
VACCINE
卷 26, 期 34, 页码 4338-4344出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.06.010
关键词
malaria vaccine; Duffy-binding protein; Plasmodium vivax; adjuvant formulation
资金
- Yerkes National Primate Research Center Base [RR00165]
- National Center for Research Resources of the National Institutes of Health, Malaria Vaccine Initiative at PATH (Program for Appropriate Technology in Health)
- Indo-US Vaccine Action Programme (VAP)
- Department of Biotechnology, Government of India
The receptor-binding domain of Plasmodium vivax Duffy-binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatto (rhesus monkeys). Recombinant PvRII with a C-terminal 6-histidine tag was expressed in E. coli, recovered from inclusion bodies, refolded into its functional conformation, purified to homogeneity and formulated with three adjuvants, namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly immunogenic. The overall magnitude of the antibody response was significantly higher for both Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there was a significant correlation between antibody recognition titers by ELISA and binding inhibition titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-gamma recall responses that were identified using ex vivo ELISPOT assays. These results provide support for further clinical development of a vaccine for P. vivax malaria based on recombinant PvRII (c) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据